Menu

Bio-Hermes

January 30, 2025 • Press Releases

Global Alzheimer’s Platform Foundation Announces Powerhouse Partnership with Biomarkers of Aging Consortium

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

Alzheimer's Alzheimers Bio-Hermes Bio-Hermes-001 Biomarkers of Aging Consortium GAP Harvard University Innovation Research
December 10, 2024 • In the News

Investors Hangout: Collaboration to Enhance Alzheimer’s Research with Eli Lilly Strategic Partnership in Alzheimer’s Research

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

Alzheimer's Alzheimers Bio-Hermes Bio-Hermes-002 GAP Innovation Lilly
October 30, 2024 • In the News

Precision Medicine Online: GAP Foundation Launches Second Study on Alzheimer’s Blood Biomarkers

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]

Alzheimer's Alzheimers Bio-Hermes Bio-Hermes-002 GAP Innovation Research
October 16, 2024 • In the News

Gov.UK Notice: Dame Barbara Windsor Dementia Mission

What we do Dementia and Neurodegeneration was identified as one of the key healthcare missions in the 2021 Life Sciences Vision. Dementia is the leading cause of death in England and one in two people will be directly affected by it – either they will care for someone with the condition, develop it themselves, or both. […]

Alzheimer's Alzheimers Bio-Hermes Bio-Hermes-002 GAP ideas Research
August 19, 2024 • In the News

Springwise: Routine eye exams could provide data to identify a patient’s disease risk earlier

An eye-based Alzheimer’s disease test Routine eye exams could provide data to identify a patient’s disease risk earlier Spotted: Dementia diagnoses appear to be increasing worldwide, most likely from a combination of ageing populations and improved awareness of the disease alongside strengthened diagnostic tools. In Canada, medical AI company RetiSpec uses commonly used eye exam images to diagnose Alzheimer’s […]

Alzheimer's Alzheimers Bio-Hermes GAP Research
August 5, 2024 • In the News

PR Newswire: iLoF Secures $1.5M Clinical Research Contract to Deploy its Optomics® Platform in Leading International Alzheimer’s Study and Expands into the US

NEWS PROVIDED BYiLoF , Jul 31, 2024, 09:28 ET The international clinical study, Bio-Hermes-002, establishes an ambitious transnational collaboration aimed at achieving a breakthrough in Alzheimer’s diagnosis and treatment. LONDON and ROCHESTER, N.Y., July 31, 2024 /PRNewswire/ — iLoF, a global deep tech digital health company, today announced it has secured a £1.2M (~$1.5M) clinical research contract from Innovate UK, […]

Alzheimer's Alzheimers Bio-Hermes Bio-Hermes-002 Research
July 11, 2024 • In the News

PharmiWeb: Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

Alzheimer's Alzheimers Bio-Hermes GAP Innovation Research
May 30, 2024 • Press Releases

First-of-its-Kind Bio-Hermes Challenge Sparks Global Interest for Novel Research

Support from Scottish Parliament Underscores Its Significance Washington D.C., May 30, 2024-  The Global Alzheimer’s Platform Foundation® (GAP)  and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes Biomarker Data Challenge 2024, the research competition using the most comprehensive set of dementia biomarker data from ground-breaking […]

ADDI Alzheimer's Alzheimers Bio-Hermes Innovation Research
May 22, 2024 • In the News

Scottish Funding Council Guest Blog: Science as a team sport

In the hands of the SFC-funded Brain Health ARC, the Bio-Hermes dataset offers the Scottish dementia research community a platform for new ideas, collaboration and early career development. Millie Mather explains more in our latest guest blog. During my working hours, I can be identified as the sole person in the room without a PhD in science or medicine. In fact, […]

Alzheimer's Alzheimers Bio-Hermes GAP Innovation Research
April 12, 2024 • In the News

TrialSiteNews: Florida Trial Site Contributes to Successful Study Testing Alzheimer’s Blood Test, Now on Market for Research, Physicians

trialsitenews Staff at TrialSite | Quality Journalism Apr. 12, 2024, 1:00 p.m. Expensive and not always covered by insurance, the standard most reliable method of diagnosing Alzheimer’s disease is via positron emission tomography or PET scan of the brain. Another more cumbersome, invasive and painful approach is the spinal tap. What if there was an […]

Alzheimers Bio-Hermes GAP Research